Your browser doesn't support javascript.
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Du, Yin-Xiao; Chen, Xiao-Ping.
  • Du YX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Chen XP; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China.
Clin Pharmacol Ther ; 108(2): 242-247, 2020 08.
Article in English | MEDLINE | ID: covidwho-30729
ABSTRACT
An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Amides Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Clin Pharmacol Ther Year: 2020 Document Type: Article Affiliation country: Cpt.1844

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Amides Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Clin Pharmacol Ther Year: 2020 Document Type: Article Affiliation country: Cpt.1844